全文获取类型
收费全文 | 1756431篇 |
免费 | 133693篇 |
国内免费 | 8686篇 |
专业分类
耳鼻咽喉 | 22255篇 |
儿科学 | 56397篇 |
妇产科学 | 47247篇 |
基础医学 | 248461篇 |
口腔科学 | 50154篇 |
临床医学 | 159604篇 |
内科学 | 341642篇 |
皮肤病学 | 39396篇 |
神经病学 | 134275篇 |
特种医学 | 66398篇 |
外国民族医学 | 274篇 |
外科学 | 263418篇 |
综合类 | 51468篇 |
现状与发展 | 18篇 |
一般理论 | 542篇 |
预防医学 | 128374篇 |
眼科学 | 42038篇 |
药学 | 131380篇 |
85篇 | |
中国医学 | 8592篇 |
肿瘤学 | 106792篇 |
出版年
2021年 | 15028篇 |
2019年 | 16024篇 |
2018年 | 22615篇 |
2017年 | 17620篇 |
2016年 | 18879篇 |
2015年 | 22425篇 |
2014年 | 30417篇 |
2013年 | 41864篇 |
2012年 | 58598篇 |
2011年 | 61623篇 |
2010年 | 36783篇 |
2009年 | 33865篇 |
2008年 | 55729篇 |
2007年 | 58836篇 |
2006年 | 58930篇 |
2005年 | 56146篇 |
2004年 | 53314篇 |
2003年 | 50395篇 |
2002年 | 48331篇 |
2001年 | 93176篇 |
2000年 | 95021篇 |
1999年 | 78311篇 |
1998年 | 19937篇 |
1997年 | 17439篇 |
1996年 | 17347篇 |
1995年 | 17555篇 |
1994年 | 15982篇 |
1993年 | 14466篇 |
1992年 | 57769篇 |
1991年 | 55692篇 |
1990年 | 53306篇 |
1989年 | 51040篇 |
1988年 | 46351篇 |
1987年 | 45149篇 |
1986年 | 42357篇 |
1985年 | 40118篇 |
1984年 | 29399篇 |
1983年 | 24905篇 |
1982年 | 13885篇 |
1979年 | 25497篇 |
1978年 | 17542篇 |
1977年 | 14860篇 |
1976年 | 13838篇 |
1975年 | 14522篇 |
1974年 | 17613篇 |
1973年 | 16916篇 |
1972年 | 15673篇 |
1971年 | 14438篇 |
1970年 | 13427篇 |
1969年 | 12506篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. 相似文献
13.
14.
de Souza Gabriel Hernandez Machado Pandolfo Mariana Travi Bortoluzzi Eduardo Antunes da Silveira Teixeira Cleonice Rossetto Hebert Luís da Rosa Amanda Freitas Machado Renata Gondo da Fonseca Roberti Garcia Lucas 《Odontology / the Society of the Nippon Dental University》2022,110(3):535-544
Odontology - The purpose of this study was to investigate whether the root perforation repair with mineral aggregate-based cements affects the retention of customized fiberglass posts to bovine... 相似文献
15.
Dong-Xin Hu Qi-Feng Sun Lin Xu Hong-Da Lu Fan Zhang Zhen-Miao Li Ming-Yan Zhang 《World journal of gastroenterology : WJG》2022,28(4):464-478
BACKGROUND Esophageal squamous cell carcinoma(ESCC)is one of the most prevalent malignancies that seriously threaten people’s health worldwide.DEAD-box helicase 51(DDX51)is a member of the DEAD-box(DDX)RNA helicase family,and drives or inhibits tumor progression in multiple cancer types.AIM To determine whether DDX51 affects the biological behavior of ESCC.METHODS The expression of DDX51 in ESCC tumor tissues and adjacent normal tissues was detected by Immunohistochemistry(IHC)analyses and quantitative PCR(qPCR).We knocked down DDX51 in ESCC cell lines by using a small interfering RNA(siRNA)transfection.The proliferation,apoptosis,and mobility of DDX51 siRNAtransfected cells were detected.The effect of DDX51 on the phosphoinositide 3-kinase(PI3K)/AKT pathway was investigated by western blot analysis.A mouse xenograft model was established to investigate the effects of DDX51 knockdown on ESCC tumor growth.RESULTS DDX51 exhibited high expression in ESCC tissues compared with normal tissues and represented a poor prognosis in patients with ESCC.Knockdown of DDX51 induced inhibition of ESCC cell proliferation and promoted apoptosis.Moreover,DDX51 siRNA-expressing cells also exhibited lower migration and invasion rates.Investigations into the underlying mechanisms suggested that DDX51 knock down induced inactivation of the PI3K/AKT pathway,including decreased phosphorylation levels of phosphate and tensin homolog,PI3K,AKT,and mammalian target of rapamycin.Rescue experiments demonstrated that the AKT activator insulin-like growth factor 1 could reverse the inhibitory effects of DDX51 on ESCC malignant development.Finally,we injected DDX51 siRNA-transfected TE-1 cells into an animal model,which resulted in slower tumor growth.CONCLUSION Our study suggests for the first time that DDX51 promotes cancer cell proliferation by regulating the PI3K/AKT pathway;thus,DDX51 might be a therapeutic target for ESCC. 相似文献
16.
17.
S. Harrogate J. Barnes K. Thomas A. Isted G. Kunst S. Gupta S. Rudd T. Banerjee R. Hinchliffe R. Mouton 《Anaesthesia》2023,78(11):1393-1408
Tobacco smoking is associated with a substantially increased risk of postoperative complications. The peri-operative period offers a unique opportunity to support patients to stop tobacco smoking, avoid complications and improve long-term health. This systematic review provides an up-to-date summary of the evidence for tobacco cessation interventions in surgical patients. We conducted a systematic search of randomised controlled trials of tobacco cessation interventions in the peri-operative period. Quantitative synthesis of the abstinence outcomes data was by random-effects meta-analysis. The primary outcome of the meta-analysis was abstinence at the time of surgery, and the secondary outcome was abstinence at 12 months. Thirty-eight studies are included in the review (7310 randomised participants) and 26 studies are included in the meta-analysis (5969 randomised participants). Studies were pooled for subgroup analysis in two ways: by the timing of intervention delivery within the peri-operative period and by the intensity of the intervention protocol. We judged the quality of evidence as moderate, reflecting the degree of heterogeneity and the high risk of bias. Overall, peri-operative tobacco cessation interventions increased successful abstinence both at the time of surgery, risk ratio (95%CI) 1.48 (1.20–1.83), number needed to treat 7; and 12 months after surgery, risk ratio (95%CI) 1.62 (1.29–2.03), number needed to treat 9. More work is needed to inform the design and optimal delivery of interventions that are acceptable to patients and that can be incorporated into contemporary elective and urgent surgical pathways. Future trials should use standardised outcome measures. 相似文献
18.
19.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
20.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献